Nazem A K, Makó J
Department of Urology, Semmelweis University Medical School, Budapest, Hungary.
Int Urol Nephrol. 1997;29(1):119-27. doi: 10.1007/BF02551427.
In long-term haemodialysis patients suffering from secondary hyperparathyroidism Se iPTH could be suppressed by an intravenous calcitriol therapy. As the Se iPTH level became reduced, lower doses of Rh-EPO were already sufficient for the maintenance of the target haematocrit, while in two patients not requiring Rh-EPO treatment an improvement of their moderate anaemia could be observed. These data corroborate the view that calcitriol is an effective drug in secondary hyperparathyroidism. The results suggest that in the improvement of renal anaemia of dialysed patients the reduction of the Se-PTH level also plays a role.
在患有继发性甲状旁腺功能亢进的长期血液透析患者中，静脉注射骨化三醇疗法可抑制血清全段甲状旁腺激素（Se iPTH）。随着Se iPTH水平降低，较低剂量的重组人促红细胞生成素（Rh-EPO）就足以维持目标血细胞比容，而在两名不需要Rh-EPO治疗的患者中，可观察到其中度贫血有所改善。这些数据证实了骨化三醇是治疗继发性甲状旁腺功能亢进的有效药物这一观点。结果表明，在改善透析患者的肾性贫血方面，降低Se-PTH水平也发挥着作用。
